NCT03852849 is a NA clinical trial of Personal involved intervention strategies in Viral Suppression of HIV Infection, sponsored by National Center for AIDS/STD Control and Prevention, China CDC.

Who is sponsoring NCT03852849?

NCT03852849 is sponsored by National Center for AIDS/STD Control and Prevention, China CDC.

What drugs are being tested in NCT03852849?

Interventions in NCT03852849: Personal involved intervention strategies, The dosage of 400mg EFV.

What condition does NCT03852849 study?

NCT03852849 studies Viral Suppression of HIV Infection.

Is NCT03852849 still recruiting?

NCT03852849 is currently status unknown. Last updated 25 February 2019.

Last reviewed 2019-02-25 · How we verify

NCT03852849

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Rapid Build of HIV Related Protective Barriers

Status unknown NA Last updated 25 February 2019

What this trial tests

NA trial testing Personal involved intervention strategies in Viral Suppression of HIV Infection in 600 participants. Status unknown.

Timeline

1 March 2019

Primary endpoint
31 December 2020

1 March 2021

Quick facts

Lead sponsor	National Center for AIDS/STD Control and Prevention, China CDC
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	single
Primary purpose	treatment
Enrollment	600
Start date	1 March 2019
Primary completion	31 December 2020
Estimated completion	1 March 2021
Sites	2 locations across China

Drugs / interventions tested

Personal involved intervention strategies
The dosage of 400mg EFV — full drug profile →

Conditions studied

Viral Suppression of HIV Infection — all drugs for Viral Suppression of HIV Infection →

Sponsor

National Center for AIDS/STD Control and Prevention, China CDC — full company profile →

Who can join

18 and older, any sex, with Viral Suppression of HIV Infection. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of the study is to screen the optimal intervention strategies to rapid establish the protective barriers against HIV-infection by maximally decreasing the viremia among HIV- infected patients.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Viral Suppression of HIV Infection

Currently open trials in the same condition.

NCT07125235 — Reactive Driven Support for Treatment, Adherence, Resilience, and Thriving (reSTART) Clinical Trial · NA · recruiting

Other National Center for AIDS/STD Control and Prevention, China CDC trials

Trials by the same sponsor.

NCT06830668 — Same-Day Restart of B/F/TAF in HIV Patients After NNRTI Discontinuation · Phase 4 · not yet recruiting
NCT01764282 — Promoting Antiretroviral Therapy Among Serodiscordant Couples to Reduce HIV Transmission · NA · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03852849 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by National Center for AIDS/STD Control and Prevention, China CDC
Last refreshed: 25 February 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03852849.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing